<VariationArchive VariationID="417458" VariationName="NC_000009.12:g.(?_95467116)_(95469931_?)del" VariationType="Deletion" Accession="VCV000417458" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2017-04-17" MostRecentSubmission="2017-04-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="396362" VariationID="417458">
      <GeneList>
        <Gene Symbol="LOC100507346" FullName="uncharacterized LOC100507346" GeneID="100507346" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>9q22.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="95463609" stop="95470019" display_start="95463609" display_stop="95470019" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="PTCH1" FullName="patched 1" GeneID="5727" HGNC_ID="HGNC:9585" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>9q22.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="95442980" stop="95516971" display_start="95442980" display_stop="95516971" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="98205263" stop="98279246" display_start="98205263" display_stop="98279246" Strand="-" />
          </Location>
          <OMIM>601309</OMIM>
          <Haploinsufficiency last_evaluated="2020-07-01" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTCH1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-07-01" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTCH1">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000009.12:g.(?_95467116)_(95469931_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>9q22.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" innerStart="95467116" innerStop="95469931" display_start="95467116" display_stop="95469931" variantLength="2816" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" innerStart="98229398" innerStop="98232213" display_start="98229398" display_stop="98232213" variantLength="2816" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.12" sequenceAccession="NC_000009" sequenceVersion="12" change="g.(?_95467116)_(95469931_?)del" Assembly="GRCh38">
            <Expression>NC_000009.12:g.(?_95467116)_(95469931_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000009.11" sequenceAccession="NC_000009" sequenceVersion="11" change="g.(?_98229398)_(98232213_?)del" Assembly="GRCh37">
            <Expression>NC_000009.11:g.(?_98229398)_(98232213_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000009.12:g.(?_95467116)_(95469931_?)del AND Gorlin syndrome" Accession="RCV000476398" Version="1">
        <ClassifiedConditionList TraitSetID="940">
          <ClassifiedCondition DB="MedGen" ID="C0004779">Gorlin syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-11-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-11-10" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-04-17" MostRecentSubmission="2017-04-17">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="940" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="381" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Basal cell nevus syndrome</ElementValue>
                <XRef ID="UWMG_1854558" DB="CSER _CC_NCGL, University of Washington" />
                <XRef Type="Phenotypic series" ID="PS109400" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gorlin syndrome</ElementValue>
                <XRef ID="69408002" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Nevoid basal cell carcinoma syndrome (NBCCS) is characterized by the development of multiple jaw keratocysts, frequently beginning in the second decade of life, and/or basal cell carcinomas (BCCs) usually from the third decade onward. Approximately 60% of individuals have a recognizable appearance with macrocephaly, frontal bossing, coarse facial features, and facial milia. Most individuals have skeletal anomalies (e.g., bifid ribs, wedge-shaped vertebrae). Ectopic calcification, particularly in the falx, is present in more than 90% of affected individuals by age 20 years. Cardiac and ovarian fibromas occur in approximately 2% and 20% of individuals respectively. Approximately 5% of all children with NBCCS develop medulloblastoma (primitive neuroectodermal tumor), generally the desmoplastic subtype. The risk of developing medulloblastoma is substantially higher in individuals with an SUFU pathogenic variant (33%) than in those with a PTCH1 pathogenic variant (&lt;2%). Peak incidence is at age one to two years. Life expectancy in NBCCS is not significantly different from average.</Attribute>
                <XRef ID="NBK1151" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7166" />
                <XRef ID="7166" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301330</ID>
                <ID Source="BookShelf">NBK1151</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2011">
                <ID Source="PubMed">21304560</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="377" DB="Orphanet" />
              <XRef ID="C0004779" DB="MedGen" />
              <XRef ID="MONDO:0007187" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS109400" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1076835" SubmissionDate="2017-03-14" DateLastUpdated="2017-04-17" DateCreated="2017-04-17">
        <ClinVarSubmissionID localKey="1275148|MedGen:C0004779" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000563917" DateUpdated="2017-04-17" DateCreated="2017-04-17" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-11-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment Type="public">This variant is a gross deletion of the genomic region encompassing exons 13-15 of the PTCH1 gene. This creates a premature translational stop signal and is expected to result in an absent or disrupted protein product. Loss-of-function variants in PTCH1 are known to be pathogenic. A deletion of exons 13-15 has been reported in an individual with Gorlin Syndrome (PMID: 22382802). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PTCH1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000009.11:g.(?_98229398)_(98232213_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0004779" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2017March_Invitae</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1076835" TraitType="Disease" MappingType="XRef" MappingValue="C0004779" MappingRef="MedGen">
        <MedGen CUI="C0004779" Name="Gorlin syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

